PUBLISHER: The Business Research Company | PRODUCT CODE: 1948349
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948349
A topical hemostat is a specialized medical product applied directly to a bleeding area during surgery or trauma to quickly promote clotting and control bleeding. These agents act locally by forming a physical barrier, triggering the body's natural clotting processes, or providing a structure that supports platelet clumping and fibrin formation to stop blood flow.
The primary types of topical hemostats include fibrin, thrombin, cellulose, collagen, gelatin, adhesives, and others. Fibrin hemostats are biologically derived agents that replicate the final stages of the coagulation process by combining fibrinogen and thrombin to form a stable clot at the bleeding site. These products are distributed through channels such as direct sales, distributors, hospital pharmacies, and online platforms, and they find application in various surgeries including general, neurosurgery, vascular, and cardiovascular procedures. Key end users comprise hospitals, ambulatory surgical centers, and other healthcare facilities.
Tariffs have influenced the topical hemostat market by increasing import costs of raw biomaterials and finished products, particularly affecting fibrin, collagen, and gelatin-based hemostats. Markets in North America and Europe are most impacted due to higher dependency on imported hemostats, while Asia-Pacific manufacturing hubs face fewer direct impacts. Some segments, such as locally produced cellulose and adhesive hemostats, may benefit as tariffs encourage regional sourcing and production. Overall, tariffs are driving manufacturers to optimize supply chains and invest in domestic production to maintain competitiveness.
The topical hemostat market research report is one of a series of new reports from The Business Research Company that provides topical hemostat market statistics, including topical hemostat industry global market size, regional shares, competitors with a topical hemostat market share, detailed topical hemostat market segments, market trends and opportunities, and any further data you may need to thrive in the topical hemostat industry. This topical hemostat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The topical hemostat market size has grown strongly in recent years. It will grow from $5.45 billion in 2025 to $5.97 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising prevalence of surgical procedures, demand for rapid hemostasis solutions, technological advancements in biomaterials, increasing hospital surgical capacity, regulatory approvals for hemostatic agents.
The topical hemostat market size is expected to see strong growth in the next few years. It will grow to $8.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growing adoption of bioactive and combination hemostats, integration with AI and digital surgery platforms, expansion of ambulatory surgical centers, focus on patient-specific hemostatic solutions, emerging markets surgical infrastructure growth. Major trends in the forecast period include minimally invasive surgical hemostasis, advanced bioactive hemostats development, patient-specific hemostatic solutions, growth in emergency & trauma care applications, expansion of outpatient & ambulatory surgical procedures.
The rising volume of surgical procedures is anticipated to drive the growth of the topical hemostat market in the coming years. Surgical procedures involve medical interventions performed by surgeons using manual methods and specialized instruments to diagnose, treat, or correct injuries, diseases, or physical abnormalities. The number of surgeries is increasing steadily due to the rapidly aging global population, which has led to a higher prevalence of age-related health conditions that require surgical treatment to enhance quality of life and manage chronic disorders. Topical hemostats are widely used during surgical procedures to enable surgeons to rapidly control bleeding at the surgical site, maintain clear visibility, reduce overall blood loss, and lower the risk of postoperative complications. For instance, in January 2025, according to Intuitive Surgical Inc., a US-based medical device company, OUS general surgery procedures rose by approximately 35% in 2024, following growth of around 42% in 2023. Colorectal procedures represented the largest portion of incremental volume in both years. As a result, the increasing number of surgical procedures is contributing to the expansion of the topical hemostat market.
Key players in the topical hemostat market are concentrating on developing innovative products such as hemostatic sealing patches to improve bleeding control during surgeries by offering faster, more effective, and targeted hemostasis at the wound site. A hemostatic sealing patch is a medical device made from materials like collagen or fibrin that rapidly stops bleeding by adhering to tissue and facilitating clot formation during surgery. For example, in November 2023, Ethicon, Inc., a US-based company specializing in surgical technologies, launched the ETHIZIA Hemostatic Sealing Patch, a new synthetic polymer-based adjunctive hemostat clinically shown to stop severe bleeding on internal organs quickly. In clinical trials, ETHIZIA halted bleeding within 30 seconds in 80% of patients, which is six times faster than leading fibrin sealant patches. The patch is uniquely designed to be effective on both sides and highly adaptable, allowing it to be trimmed, rolled, pulled apart, or customized for use in both open and minimally invasive surgeries. It dehydrates blood and speeds coagulation through a gelatin carrier infused with polyoxazoline polymer, forming a strong adhesive hydrogel that bonds firmly to tissue.
In May 2025, Merit Medical Systems Inc., a US-based global healthcare technology company, acquired BioLife Delaware LLC for approximately $120 million. With this acquisition, Merit seeks to strengthen its bleeding control portfolio by incorporating BioLife's patented topical hemostatic products, such as StatSeal and WoundSeal, thereby expanding its presence in the topical hemostat market. BioLife Delaware LLC is a US-based manufacturer of hemostatic dressings developed to rapidly control bleeding and minimize complications during interventional and surgical procedures.
Major companies operating in the topical hemostat market are Pfizer Inc, Johnson And Johnson, Medtronic Plc, Medline Industries, Stryker Corporation, Baxter International, Meril Life Sciences Pvt Ltd, Teleflex Incorporated, Samyang Holdings, Integra LifeSciences, B Braun SE, Advanced Medical Solutions Group Plc, Axio Biosolutions, Marine Polymer Technologies Inc, Hangzhou Singclean Medical Products, Neo Modulus Medical Sci-Tech, Tricol Biomedical, HemCon Medical Technologies Inc, Hemostasis LLC, KATSAN Medical Devices, Zhejiang Perfectseal New Materials, Z Medica LLC, Arch Therapeutics Inc, Medcura Inc
North America was the largest region in the topical hemostat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the topical hemostat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the topical hemostat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The topical hemostat market consists of sales of physical hemostats, active coagulation agents, synthetic and hemisynthetic agents, natural and plant-based agents, and chitosan-based dressings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Topical Hemostat Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses topical hemostat market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for topical hemostat ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The topical hemostat market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.